Clinical trial of diaminodiphenylsulfone (DDS) in nasal and nasopharyngeal rhinosporidiosis.
Rhinosporidiosis is a fairly common problem for the Otolaryngologist in many parts of the world, because of its prompt recurrence after surgical excision. Though not a fatal disease, it inflicts various kinds of social and economic strain on the patients and their families. No medical treatment has been found to be effective in controlling rhinosporidiosis. Such drugs as griseofulvin and amphotericin have been tried without much benefit. In this clinical trial with dapsone on 32 patients (71.4%) did not have recurrence in a three year period and none of them needed surgery in that period. Thirty-two patients were used as controls, and 93% of them needed surgery for recurrent rhinosporidiosis in the same three year period. Dapsone (diaminodiphenylsulfone) is a relatively safe drug to use, and no major side effects were noticed in this trial.
D003622:Dapsone / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D009302:Nasopharyngeal Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009668:Nose Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012008:Recurrence; D012227:Rhinosporidiosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D003622:Dapsone